Shanghai, China, 25 January 2022 – MicroPort Urocare Medical Technology (Jiaxing) Co., Ltd. (MicroPort® Urocare) recently obtained medical device registration certification for its single-use flexible ureteropelvic electronic endoscopic catheter from the Zhejiang Provincial Drug Administration. This is the first registration certificate that MicroPort® Urocare has obtained since its establishment in the endoscopic product category in 2017.
The ureteroscope can enter the ureter via the urethra and bladder by means of non-invasive intervention. Together with image processing equipment, it can be used to clearly observe, diagnose, and treat stones, tumors and other lesions in the ureter and inside the kidney. The single-use flexible ureteropelvic electronic endoscopic catheter approved for marketing adopts dual LED light sources at the end of the catheter tip and has 160,000 pixels for a more uniform illumination range and clearer images. The bi-directional deflection design of 270° allows flexible steering in the narrow space inside the ureter and kidney, providing the operator with a large 120° field of view.
This product from MicroPort® Urocare is the first product in China with a hydrophilic coating on the body of the mirror, which significantly reduces the coefficient of friction of the tube. In case of difficult placement of the ureteral sheath, the endoscopic catheter (i.e., bare scope) can be used alone to enter the ureter, thus reducing damage to the ureteral wall. When used with the ureteral sheath, the friction between the two can be effectively reduced, which provides an optimised experience for operators.
According to Mr. Yiyun Que, Senior Vice President of Smart Manufacturing and Global Supply Chain of MicroPort® and Chairman of MicroPort® Urocare, "So far, MicroPort® Urocare has obtained 15 registration certificates, which completes our product portfolio in the field of urological stone consumables. The launch of the single-use flexible ureteropelvic electronic endoscopic catheter is a strategic breakthrough for MicroPort® Urocare to successfully compete in the field of endoscopic solutions. We will continue to focus on clinical needs, accelerate the pace of technological innovation, and deepen our efforts in the fields of non-vascular intervention and endoscopic treatment.”
The incidence of urinary stones in China is among the top three in the world, with approximately 61.2 million patients with kidney stones within the adult population. Among them, the prevalence rate for men is 6.5%, meaning that one out of every 15 adult men suffer from kidney stones. The approval and launch of MicroPort® Urocare's single-use flexible ureteropelvic electronic endoscope provides more options for endoscopic examination and treatment of patients with urological diseases.
About MicroPort® Urocare
MicroPort® Urocare is a subsidiary of MicroPort Scientific Corporation (00853.HK, MicroPort®). MicroPort® Urocare is dedicated to the development, production and sales of diagnostic and treatment devices in the field of non-vascular intervention, covering various areas such as urology and gynecology, gastrointestinal interventions, and respiratory interventions.